Consolidation and maintenance in follicular lymphoma: radioimmunotherapy revisited?
-
Published:2018-03
Issue:3
Volume:5
Page:e96-e97
-
ISSN:2352-3026
-
Container-title:The Lancet Haematology
-
language:en
-
Short-container-title:The Lancet Haematology
Reference10 articles.
1. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study;Barr;Lancet Haematol,2018
2. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial;Salles;Lancet,2011
3. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study;Gordon;Blood,2004
4. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial;Morschhauser;J Clin Oncol,2013
5. Rituximab maintenance in follicular lymphoma: PRIMA;Friedberg;Lancet,2011